Wikipedia -WSS

Wikipedia

author：leisure time 2025-09-03 03:32:46 - browse：416

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Readout Newsletter: CAR

WSS

STAT Summit: Ending the crisis of Black deaths in the U.S.

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Roche drug slashes death risk in early

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Merck, Daiichi strike cancer drug pact worth up to $22 billion

entertainment

Wikipedia

Wikipedia

Continuity nursing helped my family in our darkest PICU moments

Study on Amgen’s bispecific immunotherapy produces positive data

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout LOUD podcast: Live from the 2023 STAT Summit

George Santos makes 1st court appearance after pleading not guilty to 13 counts

HHS secretary Becerra pressed on Change HealthCare cyberattack

What does generative AI mean for health care? We asked experts

STAT Summit: How researchers deal with rejection

BioMarin wins approval for gene therapy to treat hemophilia A

Roivant's CEO is a star, but biotech's black hole persists

entertainment

Why scientists need input from humanists on sensitive research

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

FDA clears Verve to begin U.S. study of gene

Roivant's CEO is a star, but biotech's black hole persists

How many hemophilia patients actually want gene therapy?

President Biden's budget: Here's what you might have missed

Wikipedia

entertainment

knowledge

hotspot